 |
|
Orbital Inflammatory Disease After Intravenous Infusion of Zoledronate for Treatment of Metastatic Renal Cell Carcinoma
Paul M. Phillips, MD;
Steven A. Newman, MD
Arch Ophthalmol. 2008;126(1):137-139.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Zoledronate, a bisphosphonate, is an inhibitor of osteoclastic bone resorption, indicated for treatment of osteolytic bone lesions from multiple myeloma and other solid tumors. The most common adverse effect of zoledronate is a transient flu-like syndrome. Ocular adverse effects of bisphosphonates include conjunctivitis, uveitis, episcleritis, and scleritis.1 Cases of orbital inflammatory disease have been reported after treatment with another bisphosphonate, pamidronate sodium.2-3 There have been no reported cases of orbital inflammatory disease after treatment with zoledronate. We describe a case of a man developing orbital inflammation after intravenous treatment with zoledronate for bone-involving metastases from renal cell carcinoma.
Report of a Case
A 55-year-old white man with bone metastases from renal cell carcinoma developed a transient fever (temperature,  38°C) with scleral injection in both eyes, more in the left eye than the right, one day following an infusion of 4 mg of zoledronate. By day 6, . . . [Full Text of this Article]
Comment
AUTHOR INFORMATION
|
